PBIO - Pressure BioSciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
1.8950
-0.0050 (-0.26%)
At close: 3:30PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.9000
Open1.9600
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.8000 - 1.9600
52 Week Range0.6000 - 4.4900
Volume9,626
Avg. Volume19,061
Market Cap5.986M
Beta (5Y Monthly)1.07
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
All
News
Press Releases
  • Pressure BioSciences First Quarter 2020 Financial and Business Update to Include Jim Morrison, In-Coming CEO for Merged Companies of Availa Bio
    PR Newswire

    Pressure BioSciences First Quarter 2020 Financial and Business Update to Include Jim Morrison, In-Coming CEO for Merged Companies of Availa Bio

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its First Quarter 2020 financial results and to provide a business update, including discussions on progress made in the development of the Company's proprietary Ultra Shear Technology™ ("UST™) Platform and in the pending merger of PBI, Cannaworx, and SkinScience Labs.

  • Pressure BioSciences and Leica Microsystems Sign Worldwide Co-Marketing Alliance:  The Power of Laser Microdissection, PBI's PCT Platform, and Mass Spectrometry Results in Next Generation Analysis of Tumor Biopsy Tissues
    PR Newswire

    Pressure BioSciences and Leica Microsystems Sign Worldwide Co-Marketing Alliance: The Power of Laser Microdissection, PBI's PCT Platform, and Mass Spectrometry Results in Next Generation Analysis of Tumor Biopsy Tissues

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmetics, nutraceuticals, and food & beverage industries, today announced that the Company has entered into a worldwide co-marketing agreement with German-based Leica Microsystems CMS GmbH, a Danaher company. This historic alliance is expected to offer transformative new empowerment to cancer research worldwide, by integrating the latest enabling technologies in capturing, isolating, and preparing precious biopsy samples for superior analysis of relevant biomarkers of disease state and treatment response.

  • Pressure BioSciences' $3.5 Million Order for Hand Sanitizer is a Major Indicator for Growth
    Newsfile

    Pressure BioSciences' $3.5 Million Order for Hand Sanitizer is a Major Indicator for Growth

    South Easton, Massachusetts--(Newsfile Corp. - June 12, 2020) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, was the recent subject of an article by leading publisher Small Caps Daily, concerning their latest announcement of a $3.5 million order for hand sanitizers amid the ...

  • $3,500,000 Initial Order for FDA-Registered, Premium Hand Sanitizer Catapults SkinScience Labs, a Pending Accretive Acquisition of Pressure BioSciences, Into the Multi-Billion Dollar Hand Sanitizer Market
    PR Newswire

    $3,500,000 Initial Order for FDA-Registered, Premium Hand Sanitizer Catapults SkinScience Labs, a Pending Accretive Acquisition of Pressure BioSciences, Into the Multi-Billion Dollar Hand Sanitizer Market

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that its merger partner SkinScience Labs, Inc. has received an initial $3.5 million dollar order for its newly developed, premium, dermatological hand sanitizer product. PBI announced plans on April 30, 2020 to acquire SkinScience Labs (SSL Acquisition), parent company of the award-winning Dr. Denese skin care and anti-aging product lines. PBI's rights to acquire SkinScience Labs, Inc. arise through its planned acquisition of Cannaworx, Inc., announced on April 28, 2020 (Cannaworx, Inc. Acquisition).

  • Pressure BioSciences Announces First Manufacturing Build Completely Sold Out for Revolutionary UST System for Processing Hemp-Derived Cannabinoid Oil into Stable, Water-Soluble Nanoemulsions
    PR Newswire

    Pressure BioSciences Announces First Manufacturing Build Completely Sold Out for Revolutionary UST System for Processing Hemp-Derived Cannabinoid Oil into Stable, Water-Soluble Nanoemulsions

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced the receipt of an order for the 12th and final system scheduled to be built in the Company's initial manufacturing run of its revolutionary BaroShear™ K45 processing system. Based on the Company's proprietary Ultra Shear Technology™ (UST™) platform, the BaroShear K45 is a unique and powerful nanoemulsification system designed to resolve one of the most critical problems facing the global hemp-derived cannabinoid industry today: how to make hemp-derived cannabinoid oil effectively soluble in water, to optimize absorption and bioavailability when consumed or applied. The cannabidiol market is projected to exceed $20B by 2024 (Forbes, May 2019).

  • Pressure BioSciences Announces Launch of Novel, FDA Registered Immune Booster by Pending Merger Partner Cannaworx, Inc.
    PR Newswire

    Pressure BioSciences Announces Launch of Novel, FDA Registered Immune Booster by Pending Merger Partner Cannaworx, Inc.

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that its pending merger partner Cannaworx, Inc. will be launching its patented and proprietary immune booster supplement by mid-July 2020. The Company believes that post-launch, this product could be one of the very few, and perhaps the only, OTC (over the counter), FDA registered, hemp-containing supplements with an immune booster claim.

  • Pressure BioSciences Pending Merger Partner Cannaworx, Inc. Announces Letter of Intent to Acquire Five Leaf Labs, Delivering Major Expansion of Sales and Distribution Network
    PR Newswire

    Pressure BioSciences Pending Merger Partner Cannaworx, Inc. Announces Letter of Intent to Acquire Five Leaf Labs, Delivering Major Expansion of Sales and Distribution Network

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that one of their two pending merger partners – Cannaworx, Inc. - is significantly expanding their sales and distribution network with an agreement to acquire Louisiana-based Five Leaf Labs ("FLL"). This expansion of their sales and distribution network comes at a critical time for Cannaworx, as they are anticipating the market launch of their first two products over the coming few weeks.

  • Pressure BioSciences Announces Launch of FDA-Registered Hand Sanitizer as First Product Developed Through Pending Merger Partners
    PR Newswire

    Pressure BioSciences Announces Launch of FDA-Registered Hand Sanitizer as First Product Developed Through Pending Merger Partners

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that following its previously announced pending merger (Click Here) and name change to Availa Bio, that the newly branded, publicly-traded company will be entering the hand sanitizer market through the founders of Cannaworx. The custom-designed, next generation, premium hand sanitizer will be the first product released under the new holding company Availa Bio.

  • Former L'Oréal President Jim Morrison Appointed as CEO To Lead Availa Bio Upon Merger of Pressure BioSciences, Cannaworx and SkinScience Labs
    PR Newswire

    Former L'Oréal President Jim Morrison Appointed as CEO To Lead Availa Bio Upon Merger of Pressure BioSciences, Cannaworx and SkinScience Labs

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), today announced that personal care industry leader Jim Morrison has been appointed to serve as the new CEO of the rebranded public company, Availa Bio, upon completion of the merger with Cannaworx, SkinScience Labs and Pressure BioSciences. As part of the proposed transactions, the Company intends to change the corporation's name to Availa Bio. Morrison has had a legendary career including numerous leadership positions in the personal care industry, most notably as President of L'Oréal. While at L'Oréal, Morrison oversaw growth that averaged more than 20% year-over-year. He engineered the acquisitions of Redken and Matrix and led the company during a period of unprecedented growth during his tenure.

  • Pressure BioSciences Announces Planned Name Change to "Availa Bio" Following Completion of Cannaworx and SkinScience Labs Transactions
    PR Newswire

    Pressure BioSciences Announces Planned Name Change to "Availa Bio" Following Completion of Cannaworx and SkinScience Labs Transactions

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced its intention to change the corporation's name to Availa Bio upon completion of the acquisitions and merger of Cannaworx, Inc. and SkinScience Labs, Inc. with PBI. The three companies will operate as synergistic divisions within the combined "Availa Bio" entity. This strategic change in corporate identity and branding reflects the science-driven collaboration of the companies focused on the overarching priority of leveraging the revolutionary Ultra Shear Technology™(UST™) platform to bring significant new value to consumers in optimized bioavailability, absorption, quality and performance across Availa Bio's diverse range of human, animal and agricultural products being introduced in the coming months or already on market.

  • Pressure BioSciences' Recently Announced Acquisitions Advance the Company Forward
    Newsfile

    Pressure BioSciences' Recently Announced Acquisitions Advance the Company Forward

    New York, New York--(Newsfile Corp. - May 4, 2020) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, was recently covered by leading publisher Small Caps Daily concerning their recently announced accretive acquisitions which position the Company to expand into several lucrative markets. ...

  • Pressure BioSciences, Through Cannaworx, Inc., Announces Letter of Intent to Acquire SkinScience Labs, Inc.
    PR Newswire

    Pressure BioSciences, Through Cannaworx, Inc., Announces Letter of Intent to Acquire SkinScience Labs, Inc.

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced a letter of intent to acquire SkinScience Labs, Inc., parent company of the award-winning Dr. Denese skin care and anti-aging product lines. The rights to acquire SkinScience Labs, Inc., which includes Dr. Denese SkinScience, is through Cannaworx, Inc. PBI announced plans on April 28, 2020 to acquire Cannaworx, Inc. (Click here).

  • Pressure BioSciences Announces Plans to Acquire Cannaworx, Inc.
    PR Newswire

    Pressure BioSciences Announces Plans to Acquire Cannaworx, Inc.

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that it has signed a binding letter of intent to merge with Cannaworx, Inc. (USA) and its diverse portfolio of products and intellectual property developed by its founders Bobby Ghalili, DMD and Adrienne Denese, MD, PhD.

  • Pressure BioSciences and RedShiftBio Demonstrate Potential of Combining Proprietary Technologies to Enable New Tool for Development and Production of Biotherapeutics
    PR Newswire

    Pressure BioSciences and RedShiftBio Demonstrate Potential of Combining Proprietary Technologies to Enable New Tool for Development and Production of Biotherapeutics

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced that the combination of PBI's patented Pressure Cycling Technology ("PCT") with RedShiftBio's proprietary Microfluidic Modulation Spectroscopy ("MMS") resulted in a powerful new platform for biotherapeutic drug development ("PCT-enhanced MMS"). The Company believes combining both platforms enables the rigorous investigation of protein structure and stability in a streamlined and highly efficient workflow that can be critical in drug development.

  • Pressure BioSciences Nearing Complete Sellout on Pre-launch Offering of Game-Changing UST System for Processing CBD Oil Into Water-soluble Nanoemulsions
    PR Newswire

    Pressure BioSciences Nearing Complete Sellout on Pre-launch Offering of Game-Changing UST System for Processing CBD Oil Into Water-soluble Nanoemulsions

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company has received a purchase order from a new customer, Can B Corp (OTC: CANBD), for one of its proprietary BaroShear K45 Ultra Shear Technology™ ("UST™")-based systems for processing CBD Oil into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water. Such nanoemulsions are expected to exhibit levels of bioavailability that far exceed the absorption efficiency of today's macro or microemulsions of CBD Oil.

  • Pressure BioSciences Launches New Era in Preparation of Water-Soluble Nanoemulsions, for CBD and Other Valuable Oils, with Opening of UST Demonstration Laboratory
    PR Newswire

    Pressure BioSciences Launches New Era in Preparation of Water-Soluble Nanoemulsions, for CBD and Other Valuable Oils, with Opening of UST Demonstration Laboratory

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced the official opening of its new Ultra Shear Technology™ ("UST™") Demonstration Laboratory (the "UST Demo Lab"). The UST Demo Lab is located in the Company's South Easton, Massachusetts facility.

  • Zacks Small Cap Research Releases Updated Report on Pressure BioSciences, Inc.
    PR Newswire

    Zacks Small Cap Research Releases Updated Report on Pressure BioSciences, Inc.

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that Zacks Small Cap Research ("Zacks SCR") has released an updated research report in its on-going coverage on the Company.

  • Pressure BioSciences Accelerating Rollout of Proprietary UST Platform for Water-Soluble CBD with Planned Release of Additional BaroShear Instrument
    PR Newswire

    Pressure BioSciences Accelerating Rollout of Proprietary UST Platform for Water-Soluble CBD with Planned Release of Additional BaroShear Instrument

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company plans to release a benchtop, R&D; scale, Ultra Shear Technology™ ("UST™")-based BaroShear instrument to the market in the third quarter of 2020. The Company believes this new instrument will address a significant un-met need in product formulation and development laboratories in the cannabis, cosmetics, nutraceuticals, pharmaceuticals, and other large and diverse markets for processing CBD and other oils into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water.

  • Pressure BioSciences Announces Significant New Order and Near Sellout on Revolutionary Nanoemulsification System for Water-Soluble CBD Oil
    PR Newswire

    Pressure BioSciences Announces Significant New Order and Near Sellout on Revolutionary Nanoemulsification System for Water-Soluble CBD Oil

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company has received a purchase order from a new customer for six (6) proprietary Ultra Shear Technology™ ("UST™")-based nanoemulsification systems for processing CBD Oil into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water. Such nanoemulsions are expected to exhibit levels of bioavailability that far exceed the bioavailability of today's macro or microemulsions of CBD Oil.

  • Pressure BioSciences' Revolutionary UST Platform Featured in Leading North American Cannabis Magazine
    Newsfile

    Pressure BioSciences' Revolutionary UST Platform Featured in Leading North American Cannabis Magazine

    Cannabis Brightline Article Highlights Potential of PBI's UST Platform to Play Significant Role in Multiple Billion Dollar Markets - Including CBD, Cosmetics, Nutraceuticals, Biopharmaceuticals, and Food/Beverage South Easton, Massachusetts--(Newsfile Corp. - January 17, 2020) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company's new ...

  • Number of Published Scientific Papers Citing the Advantages of Pressure BioSciences' PCT Platform Remained Strong in 2019
    Newsfile

    Number of Published Scientific Papers Citing the Advantages of Pressure BioSciences' PCT Platform Remained Strong in 2019

    For the Second Straight Year, Over 20 Journal Articles Highlight the Benefits of PBI's Patented PCT Platform in Such Critical Areas of Research as Cancer, Food Safety, and Proteomics South Easton, Massachusetts--(Newsfile Corp. - January 9, 2020) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today announced that in ...

  • GlobeNewswire

    Pressure BioSciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

    Significant Revenue Growth Reported in Consumable Products (158%) and Scientific Services (87%);Company Continues to Gain Momentum in Its PCT, BaroFold, and UST Technology.

  • GlobeNewswire

    Pressure BioSciences, Inc. to Discuss Third Quarter 2019 Financial Results and Provide Business Update

    SOUTH EASTON, Mass., Dec. 18, 2019 -- via OTC PR WIRE – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”) today announced that the Company will host a.

  • GlobeNewswire

    Zacks Small Cap Research Initiates Coverage on Pressure BioSciences, Inc.

    SOUTH EASTON, Mass., Oct. 04, 2019 -- via OTC PR WIRE – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly.

  • GlobeNewswire

    Pressure BioSciences’ Proprietary PCT Platform Fills Pivotal Role for Tumor Analyses in Novel Workflow Presented at Leading Global Gynecologic Cancer Meeting

    SOUTH EASTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Pressure BioSciences, Inc. (PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced the Company’s patented pressure cycling technology (“PCT”) platform was featured as an integral part of a new, innovative workflow for the analysis of proteins from cancer biopsy samples.  This workflow was presented in a plenary session at the Annual Meeting of the International Gynecologic Cancer Society (“IGCS”) on September 21, 2019 in Rio de Janeiro, Brazil. The mission of the IGCS is to improve the care and outcomes for women with gynecologic cancer worldwide through education, training and public awareness.